Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.
Crohn’s disease
persistence
sarcopenia
ustekinumab
Journal
Therapeutic advances in chronic disease
ISSN: 2040-6223
Titre abrégé: Ther Adv Chronic Dis
Pays: United States
ID NLM: 101532140
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
09
2022
accepted:
03
07
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Ustekinumab was approved in 2016 for the treatment of moderate-severe Crohn's disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologics in CD. We assessed the 2-year real-world effectiveness and safety of ustekinumab in a tertiary CD cohort with the use of novel imaging techniques. Retrospective cohort study. Retrospective data were collected between 2016 and 2021. Study end points included ustekinumab persistence, biological and/or clinical response and remission at 12, 18 and 24 months. Statistical analysis included demographic and inferential analyses. In all, 131 CD patients [57.3% female, median age of 26.0 (21.0-37.0)] were included. Patients were non-bio naïve, and the majority received ustekinumab as third- or fourth-line treatment. At 24 months, 61.0% (80/131) persisted with ustekinumab [52.7% (69/131) steroid free]. Clinical response was reported in 55.2% (37/67), clinical remission in 85.7% (57/67), biological response in 46.8% (22/47) and biological remission in 31.9% (15/47) of patients at 24 months. The low outcome numbers were attributable to missing data. Improvements in routine disease markers, including C-reactive protein and Harvey-Bradshaw Index, were also reflected in magnetic resonance imaging-derived disease scores. The presence of penetrating CD, an -ostomy and sarcopenia were all predictors of poorer ustekinumab outcomes ( Ustekinumab is effective in non-bio-naïve CD patients with non-stricturing, non-penetrating disease with an unremarkable safety profile but may be less effective in those with penetrating disease, -ostomies and sarcopenia.
Sections du résumé
Background
UNASSIGNED
Ustekinumab was approved in 2016 for the treatment of moderate-severe Crohn's disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologics in CD.
Objectives
UNASSIGNED
We assessed the 2-year real-world effectiveness and safety of ustekinumab in a tertiary CD cohort with the use of novel imaging techniques.
Design
UNASSIGNED
Retrospective cohort study.
Methods
UNASSIGNED
Retrospective data were collected between 2016 and 2021. Study end points included ustekinumab persistence, biological and/or clinical response and remission at 12, 18 and 24 months. Statistical analysis included demographic and inferential analyses.
Results
UNASSIGNED
In all, 131 CD patients [57.3% female, median age of 26.0 (21.0-37.0)] were included. Patients were non-bio naïve, and the majority received ustekinumab as third- or fourth-line treatment. At 24 months, 61.0% (80/131) persisted with ustekinumab [52.7% (69/131) steroid free]. Clinical response was reported in 55.2% (37/67), clinical remission in 85.7% (57/67), biological response in 46.8% (22/47) and biological remission in 31.9% (15/47) of patients at 24 months. The low outcome numbers were attributable to missing data. Improvements in routine disease markers, including C-reactive protein and Harvey-Bradshaw Index, were also reflected in magnetic resonance imaging-derived disease scores. The presence of penetrating CD, an -ostomy and sarcopenia were all predictors of poorer ustekinumab outcomes (
Conclusion
UNASSIGNED
Ustekinumab is effective in non-bio-naïve CD patients with non-stricturing, non-penetrating disease with an unremarkable safety profile but may be less effective in those with penetrating disease, -ostomies and sarcopenia.
Identifiants
pubmed: 37601038
doi: 10.1177/20406223231189072
pii: 10.1177_20406223231189072
pmc: PMC10434845
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20406223231189072Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Aliment Pharmacol Ther. 2020 May;51(10):948-957
pubmed: 32249966
Nutrition. 2022 Feb;94:111526
pubmed: 34861460
Gastroenterology. 2019 Aug;157(2):432-439.e1
pubmed: 30953614
PLoS One. 2017 Jun 23;12(6):e0180036
pubmed: 28644887
Dtsch Arztebl Int. 2009 Feb;106(8):123-33
pubmed: 19568370
Aliment Pharmacol Ther. 2017 May;45(9):1255-1264
pubmed: 28244124
Inflamm Bowel Dis. 2017 May;23(5):833-839
pubmed: 28328624
Eur Radiol. 2014 Feb;24(2):277-87
pubmed: 24026620
United European Gastroenterol J. 2020 May;8(4):418-424
pubmed: 32213026
Drugs. 2017 Jul;77(10):1105-1114
pubmed: 28528528
Aliment Pharmacol Ther. 2017 May;45(9):1232-1243
pubmed: 28252210
Intest Res. 2020 Jan;18(1):79-84
pubmed: 32013316
Cancer Manag Res. 2019 Apr 01;11:2579-2588
pubmed: 31114324
Clin Imaging. 2021 Jan;69:50-62
pubmed: 32653818
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
Aliment Pharmacol Ther. 2013 Mar;37(5):537-45
pubmed: 23289713
Eur Radiol. 2016 Jul;26(7):2107-17
pubmed: 26433956
J Clin Med. 2019 Dec 04;8(12):
pubmed: 31817134
Surg Today. 2020 Oct;50(10):1138-1150
pubmed: 31617016
Clin Colon Rectal Surg. 2007 Nov;20(4):309-13
pubmed: 20011427
Frontline Gastroenterol. 2015 Jul;6(3):169-174
pubmed: 28839807
J Crohns Colitis. 2020 Jan 1;14(1):33-45
pubmed: 31219157
J Crohns Colitis. 2020 May 21;14(4):557-566
pubmed: 31541235
World J Gastroenterol. 2019 Aug 21;25(31):4481-4492
pubmed: 31496626
Lancet. 2012 Nov 3;380(9853):1590-605
pubmed: 22914295
J Crohns Colitis. 2019 Oct 28;13(11):1401-1409
pubmed: 30989232
World J Gastroenterol. 2016 Jan 21;22(3):917-32
pubmed: 26811637
Aliment Pharmacol Ther. 2019 Aug;50(3):278-288
pubmed: 31222872
Crohns Colitis 360. 2020 Aug 01;2(3):otaa064
pubmed: 36776498
BMC Med Imaging. 2016 May 05;16(1):37
pubmed: 27149857
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
Aliment Pharmacol Ther. 2015 Mar;41(5):419-28
pubmed: 25580985
Frontline Gastroenterol. 2019 May 29;11(2):111-116
pubmed: 32133109
Dig Dis Sci. 2022 Mar;67(3):1018-1035
pubmed: 33723700
J Crohns Colitis. 2013 Aug;7(7):e256-62
pubmed: 23140840
JGH Open. 2021 Feb 02;5(3):364-370
pubmed: 33732883
Inflamm Bowel Dis. 2019 Jan 1;25(1):67-73
pubmed: 29889230
Gut. 2009 Aug;58(8):1113-20
pubmed: 19136510
F1000Res. 2019 Jul 29;8:
pubmed: 31448080
Nutrients. 2021 Feb 17;13(2):
pubmed: 33671473
Aliment Pharmacol Ther. 2020 Sep;52(6):1017-1030
pubmed: 32770851
Eur J Gastroenterol Hepatol. 2020 Dec;32(12):1507-1513
pubmed: 32868649
Therap Adv Gastroenterol. 2018 Apr 13;11:1756284818765956
pubmed: 29686731
Dis Mon. 2018 Feb;64(2):20-57
pubmed: 28826742
J Crohns Colitis. 2018 Feb 28;12(3):313-320
pubmed: 29182750
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508